grant
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2)
Organization MAYO CLINIC ROCHESTERLocation ROCHESTER, UNITED STATESPosted 15 Sept 2019Deadline 31 Aug 2030
NIHUS FederalResearch GrantFY2025AD dementiaAD related dementiaADRDAbbreviationsAccuracy of DiagnosisAchievementAchievement AttainmentAddressAffectAgeAlzheimer Type DementiaAlzheimer disease dementiaAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's DiseaseAlzheimer's and related dementiasAlzheimer's dementia and related dementiaAlzheimer's dementia or related dementiaAlzheimer's disease and related dementiaAlzheimer's disease and related disordersAlzheimer's disease or a related dementiaAlzheimer's disease or a related disorderAlzheimer's disease or related dementiaAlzheimer's disease related dementiaAlzheimers DementiaApplications GrantsAutopsyBehavioralBiologicalBiological MarkersBloodBlood Reticuloendothelial SystemBlood SampleBlood specimenBody TissuesC9ORF72Cerebrospinal FluidClinicalClinical DataClinical TrialsClinical Trials DesignCognitiveCollectionCommunitiesDNA mutationDNA-Binding ProteinsDataData CollectionDegenerative Neurologic DisordersDevelopmentDiseaseDisease ProgressionDisorderEnrollmentEvaluationFTD dementiaFTLDFamilial diseaseFamilyFosteringFrontal Temporal DementiaFrontal Temporal Lobar DegenerationFrontotemporal DementiaFrontotemporal Lobar DegenerationsFrontotemporal variety lobar degenerationFundingGenesGeneticGenetic ChangeGenetic defectGenetic mutationGoalsGrantGrant ProposalsHereditaryHistoryImageIndividualIndustryInfrastructureInheritedKnowledgeLaboratoriesMAPT geneMAPT proteinMRI ScansMT-bound tauMTBT1Magnetic Resonance Imaging ScanManuscriptsMeasurementMeasuresMethodologyMethodsMicrotubule-Associated ProteinsMolecular WeightMotorMutateMutationNational Institutes of HealthNervous System Degenerative DiseasesNeural Degenerative DiseasesNeural degenerative DisordersNeurodegenerative DiseasesNeurodegenerative DisordersNeurologic Degenerative ConditionsNorth AmericaPC cell-derived growth factorPCDGFPGRN genePGRN proteinParticipantPatientsPersonsPhasePreparationPrimary Senile Degenerative DementiaProgranulinProtocolProtocols documentationPublishingRecommendationRecording of previous eventsResearchSamplingScanningSymptomsTechnology AssessmentTestingTimeTissuesUnited States National Institutes of Healthagesarmbio-markersbiologicbiologic markerbiomarkercerebral spinal fluidchromosome 9 open reading frame 72cohortcomputer based predictiondata sharingdegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdepositorydesigndesigningdevelopmentaldiagnostic accuracyeffective therapyeffective treatmentenrollfamilial disorderfront temporal dementiafrontal lobe dementiafrontotemporal lobar degeneration dementiafrontotemporal lobar dementiafrontotemporal lobe degeneration associated with dementiagene productgenome mutationgranulin precursorhigh riskhistoriesimagingimprovedinsoluble aggregatekindredmeetingmeetingsmicrotubule associated protein taumicrotubule bound taumicrotubule-associated protein taumicrotubule-bound taunecropsyneural imagingneuro-imagingneurodegenerative illnessneuroimagingneurological imagingneuropathologicneuropathologicalneuropathologynew drug treatmentsnew drugsnew pharmacological therapeuticnew technologynew therapeuticsnew therapynext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel technologiesnovel therapeuticsnovel therapypatient advocacy groupphenotypic datapostmortempredictive modelingpreparationspreventpreventingprimary degenerative dementiaprogramsprogranulin geneprogranulin proteinprotein aggregateprotein aggregationremote assessmentremote evaluationrepositorysample collectionsenile dementia of the Alzheimer typespecific biomarkersspecimen collectionspinal fluidtautau Proteinstau factortooltreatment trialτ Proteins
Description preview
ABSTRACT – ALLFTD2: OVERALL SECTION
Frontotemporal lobar degeneration (FTLD) is an overarching term for a group of neurodegenerative disorders
associated with the accumulation of toxic protein aggregates in the CNS, most commonly comprised of one of
two major proteins—microtubule associated protein tau (i.e., FTLD-tau) and TAR DNA binding protein…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click